Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 11/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 10/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 7/20 | 0.46 |
| ▸ | NCOR2 | Q9Y618 | 7/20 | 0.46 |
| ▸ | PRCP | P42785 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29763648 | 1.00 | HDAC8 (0.48) | HDAC8HDAC1HDAC2HDAC3NCOR2 | |
| SCHEMBL30286814 | 0.85 | HDAC8 (0.57) | HDAC8HDAC1HDAC2HDAC3NCOR2 | |
| SCHEMBL24419866 | 0.85 | HDAC8 (0.57) | HDAC8HDAC1HDAC2HDAC3NCOR2 | |
| SCHEMBL29763657 | 0.85 | TERT (0.47) | HDAC8HDAC1HDAC2HDAC3NCOR2 | |
| SCHEMBL24419941 | 0.84 | HHAT (0.45) | — | |
| SCHEMBL23948095 | 0.77 | HDAC8 (0.46) | HDAC8HDAC1HDAC2HDAC3NCOR2 | |
| SCHEMBL30286803 | 0.77 | HDAC8 (0.46) | HDAC8HDAC1HDAC2HDAC3NCOR2 | |
| SCHEMBL14417385 | 0.76 | PRCP (0.70) | HDAC8HDAC1HDAC2HDAC3NCOR2 | |
| SCHEMBL6227770 | 0.75 | C5AR1 (0.42) | HDAC8HDAC1HDAC2HDAC3NCOR2 | |
| SCHEMBL6227774 | 0.75 | C5AR1 (0.42) | HDAC8HDAC1HDAC2HDAC3NCOR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4135698-A2 | SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS | The Trustees of Indiana University (US) | 2023-02-22 | — | — | EP | disclosed |
| US-20230047626-A1 | SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS | THE TRUSTEES OF INDIANA UNIVERSITY | 2023-02-16 | — | — | US | disclosed |
| US-20220142973-A1 | SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS | THE TRUSTEES OF INDIANA UNIVERSITY | 2022-05-12 | — | — | US | disclosed |
| WO-2021212010-A2 | SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2021-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230047626-A1 | SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS | TP53, EIF2AK2, POLI | HDAC8 988/4885HDAC1 935/4885HDAC2 2061/4885 |
| US-20220142973-A1 | SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS | TP53, EIF2AK2, POLI | HDAC8 988/4885HDAC1 935/4885HDAC2 2061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.